ABSTRACT
Enterococcal bloodstream infections (BSI) caused by Enterococcus faecalis and Enterococcus faecium present significant public health concerns, particularly with rising vancomycin resistance (VRE). This study aimed to estimate the causal effect of two empiric strategies— immediate VRE coverage (daptomycin or linezolid) versus initial vancomycin or ampicillin with potential escalation—by emulating a target trial in electronic health records. We identified adult patients with positive blood cultures for E. faecalis or E. faecium from January 2017 to January 2023. Patients were assigned to immediate VRE coverage or initial VSE-active therapy with escalation within three days if clinical deterioration or new microbiologic data warranted. Using inverse probability weighting, we adjusted for baseline factors (e.g., age, comorbidities, prior antibiotic use) and time-varying confounders (changes in severity). Our intention-to-treat (ITT) and per-protocol analyses estimated 30-day all-cause mortality, with additional sensitivity analyses at 10 and 15 days. Among 799 patients, 45 (5.6%) received VRE-targeted therapy at baseline. The ITT analysis indicated a 1.35 percentage point mortality reduction (95% CI: –7.2% to 7.9%) with universal immediate VRE coverage, and the per-protocol analysis showed a risk difference of –3.76 points (95% CI: –14.9% to 20.4%). Sensitivity analyses yielded similar findings. In this population, immediate VRE coverage did not confer a clear survival advantage over standard therapy with potential escalation, supporting clinical equipoise and highlighting the need for larger trials (randomized or target trials) to evaluate optimal empiric regimens for enterococcal BSI.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Institutes of Health grants AI137336 and AI140754 (B.S. and V.J.T.); grants CDC U01CK000590 (B.S.); U48 DP006396-01 (L.E.T.); AI149350 (V.J.T.); and funds from the NYU Langone Health AMR Program (B.S., V.J.T.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB at New York University Langone Medical Center (NYULMC) gave ethical approval for this work as an activity of the Antimicrobial-Resistant Pathogens Program
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors after proper de-identification.
